



## Stem Cells and Cancer Therapeutics

Guest Editors:

### Dr. Anna Vert

Stem Cells and Cancer Research  
Laboratory, CIBERONC. Institut  
Hospital del Mar Investigacions  
Mèdiques (IMIM), 08003  
Barcelona, Spain

### Dr. Lluís Espinosa

Stem Cells and Cancer Research  
Laboratory, CIBERONC. Institut  
Hospital del Mar Investigacions  
Mèdiques (IMIM), 08003  
Barcelona, Spain

Deadline for manuscript  
submissions:

**closed (30 September 2018)**

### Message from the Guest Editors

Dear Colleagues,

Stem cells are defined as cells with the ability to self-renew and to differentiate into multiple lineages. This definition applies to both physiologic and pathologic conditions. In the case of cancer, multiple experimental evidences support the existence of specific cell populations that are functionally identified for their capacity to initiate and propagate tumors. These cells have been classically called tumor initiating cells (TICs) or cancer stem cells (CSCs) and are supposed to possess stem cell-like properties, including long-term self-renewal, capacity of multi-lineage differentiation, increased resistance to therapy, and the ability to promote tumor relapse and metastasis. This special issue will focus on understanding the molecular mechanisms that control normal and cancer-related stemness and the tools that are currently available for studying them both in vitro and in vivo. In particular, we will pay attention in how TICs contribute to cancer progression and therapy resistance, and the possibility of specifically targeting TIC in anti-cancer therapies.

Dr. Anna Vert

Dr. Lluís Espinosa

Guest Editors





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)